ELZA Institute, Dietikon/Zurich.
Laboratory of Ocular Cell Biology, Center for Applied Biotechnology and Molecular Medicine, University of Zurich, Zurich.
Curr Opin Ophthalmol. 2023 Jul 1;34(4):339-347. doi: 10.1097/ICU.0000000000000967. Epub 2023 Apr 25.
The aim of this study was to summarize the recent developments in corneal cross-linking (CXL) and its indications, including corneal ectasias, refractive surgery and infectious keratitis.
Advances in CXL technology, such as the use of higher-intensity LED ultraviolet (UV) light sources and a better understanding of the UV-riboflavin photochemical reaction, have enabled safer and more effective methods of cross-linking thin and ultra-thin corneas, and more effective accelerated transepithelial/'epi-on' CXL procedures that are beginning to supplant the Dresden protocol as the 'gold standard' CXL method. CXL is also being used in combination with laser surgery, not only to expand the patient base who can receive refractive surgery, but also to help rehabilitate vision in patients with ectasia. CXL, and CXL combined with photorefractive keratectomy (PRK), can result in corneal flattening of 1-2 D, and corneal regularization of 4-5 D, respectively. Finally, photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has been shown to be an effective therapy for infectious keratitis, both alone, and in combination with antimicrobial drugs.
CXL has evolved from a single technique to treat a single corneal ectasia, keratoconus, to several techniques with several indications, spanning a spectrum of corneal ectasias, as well as visual rehabilitation, refractive procedures and infectious keratitis treatment.
本研究旨在总结近年来角膜交联术(CXL)及其适应证的进展,包括角膜扩张、屈光手术和感染性角膜炎。
CXL 技术的进步,如使用高强度 LED 紫外线(UV)光源和更好地理解 UV-核黄素光化学反应,使得交联薄角膜和超薄角膜的方法更安全、更有效,更有效的加速经上皮/“epi-on”CXL 程序开始取代德累斯顿方案作为“金标准”CXL 方法。CXL 也与激光手术联合使用,不仅扩大了可以接受屈光手术的患者群体,而且有助于恢复扩张患者的视力。CXL 和 CXL 联合光性折射性角膜切除术(PRK)可分别使角膜平坦化 1-2D 和角膜规则化 4-5D。最后,光激活染色质用于角膜炎-角膜交联术(PACK-CXL)已被证明是一种有效的治疗感染性角膜炎的方法,单独使用或与抗菌药物联合使用均可。
CXL 已从一种单一技术发展成为一种单一适应证的技术,用于治疗一种角膜扩张症,即圆锥角膜,现在已经发展成了多种技术,具有多种适应证,涵盖了一系列的角膜扩张症,以及视力康复、屈光手术和感染性角膜炎的治疗。